On November 2, 2021 iOnctura SA, a clinical stage oncology company targeting core resistance and relapse mechanisms at the tumor-stroma-immune interface, reported that it will present preclinical data on its next generation autotaxin inhibitor, IOA-289, at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Annual Meeting taking place on November 10–14, 2021 in Washington, D.C. and virtually (Press release, iOnctura, NOV 2, 2021, View Source [SID1234640244]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
IOA-289 will be the first autotaxin inhibitor to be clinically investigated in oncology. It is currently being evaluated in healthy volunteers as a lead-in to a Phase I clinical study in pancreatic cancer.
The presentation at SITC (Free SITC Whitepaper) is entitled "A novel autotaxin inhibitor, IOA-289, modulates tumor, immune and stromal cell function and has monotherapy activity in fibrotic cancer models." The poster will be presented on Saturday November 13th between 7.00 and 8.30 am EST (13.00-14.30 CET), 12.30-2.00 pm EST (18.30-20.00 CET) and 7.00-8.30 pm EST (01.00-02.30 CET on November 14). It will be available for viewing on the SITC (Free SITC Whitepaper) virtual meeting platform from 7.00 am EST (13.00 CET) on Friday November 12, 2021 until the close of the platform on January 9, 2022.
Contacts
iOnctura
Catherine Pickering
Chief Executive Officer
T : +41 79 952 72 52
E: [email protected]
Press Relations
Jeremy Nieckowski
LifeSci Advisors
T: +41 79 699 97 27
E: [email protected]
iOnctura SA is clinical stage oncology company targeting core resistance and relapse mechanisms at the tumor-stroma-immune interface. iOnctura’s best-in-class drug development programs combine immune-mediated and direct anti-tumour activity to deliver molecules with superior clinical efficacy and safety in oncology. Its lead program, IOA-244 is the only semi-allosteric PI3Kdelta specific, orally dosed, small molecule inhibitor that is being developed in solid and hematological malignancies to address tumor and stroma induced immune suppression. IOA-244 is currently in Part B of a Phase 1 study. iOnctura’s second program, IOA-289, is an oral small molecule that inhibits the cross-talk between the tumor and its stroma and is in a Phase 1 clinical study. iOnctura is backed by blue chip investors including M Ventures, Inkef Capital, VI Partners, Schroders Capital, and 3B Future Health Fund. For more information, please visit www.ionctura.com
IOA-289, originally licensed from Cancer Research UK, is iOnctura’s second clinical compound, a next generation oral small molecule autotaxin inhibitor that is currently being investigated in the healthy volunteer stage of the AION 01 trial, a phase 1 clinical study in pancreatic cancer. iOnctura has undertaken extensive validation of the autotaxin inhibition mechanism in multiple preclinical solid tumor models.